Immucell Corp (ICCC) Boosts Q2 Sales Outlook

Immucell Corp (NASDAQ: ICCC) announced an improvement in its product sales forecast guidance for the second quarter of 2015 to an increase in the range of 25% to 30% in comparison to the second quarter of 2014, from the previously announced anticipated decrease in the range of 15% to 20%, subject to the risks and uncertainties identified below under the "Safe Harbor Statement".

Michael F. Brigham, President and CEO, commented, "This increase in guidance is due primarily to a better-than-expected inventory production schedule allowing us to address a portion of the pent-up demand that is building for First Defense®. Despite shipping all the First Defense®that we can produce, we still have a backlog of orders waiting to be shipped aggregating approximately $1.45 million as of June 30, 2015 (as compared to $1.28 million as of March 31, 2015). We remain on track to complete all of our planned manufacturing capacity expansion investments by the first quarter of 2016. We expect year-to-date product sales to be approximately 40% higher than the first six months of 2014, and we continue to expect positive year-to-date sales growth throughout 2015, in comparison to the same periods in 2014."

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• OptiNose (OPTN) Provides Corporate Update on XHANCE Launch
• WWP, Plc (WPP) Issues Q1 Trading Update